BRISTOL MYERS SQUIBB
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
- Conditions
- Unresectable or Metastatic Melanoma
- Interventions
- First Posted Date
- 2012-11-06
- Last Posted Date
- 2022-04-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 405
- Registration Number
- NCT01721746
- Locations
- 🇺🇸
Levine Cancer Institute, Charlotte, North Carolina, United States
🇺🇸San Francisco Oncology Associates, San Francciso, California, United States
🇺🇸UCSD Moores Cancer Center, La Jolla, California, United States
A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects
- Conditions
- Hepatitis C Virus Infection
- Interventions
- First Posted Date
- 2012-10-31
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 258
- Registration Number
- NCT01718145
- Locations
- 🇯🇵
Local Institution, Saitama, Japan
Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy
- Conditions
- Hepatitis C
- Interventions
- Biological: Peginterferon Alfa-2aBiological: Peginterferon Lambda-1aDrug: RibavirinDrug: DaclatasvirDrug: Telaprevir
- First Posted Date
- 2012-10-31
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 444
- Registration Number
- NCT01718158
- Locations
- 🇺🇸
Nashville Medical Research Institute, Nashville, Tennessee, United States
🇺🇸Va Long Beach Healthcare System, Long Beach, California, United States
🇬🇧Local Institution, London, Greater London, United Kingdom
A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors
- First Posted Date
- 2012-10-26
- Last Posted Date
- 2023-02-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 337
- Registration Number
- NCT01714739
- Locations
- 🇺🇸
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇺🇸UPMC Eye and Ear Institute, Pittsburgh, Pennsylvania, United States
🇺🇸Beth Israel Deaconess Med Ctr, Boston, Massachusetts, United States
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
- Conditions
- Lupus Nephritis
- Interventions
- Biological: BMS-188667Drug: Mycophenolate mofetilBiological: Placebo matching with BMS-188667Drug: Prednisone
- First Posted Date
- 2012-10-26
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 695
- Registration Number
- NCT01714817
- Locations
- 🇨🇴
Riesgo De Fractura S.A. Cayre Ips, Bogota, Cundinamarca, Colombia
🇨🇴Circaribe S.A.S, Barranquilla, Colombia
🇨🇴Servimed E.U, Bucaramanga, Santander, Colombia
Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma
- Conditions
- Melanoma
- Interventions
- Biological: IpilimumabDrug: Chemotherapy
- First Posted Date
- 2012-10-18
- Last Posted Date
- 2015-11-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 31
- Registration Number
- NCT01709162
- Locations
- 🇺🇸
Birmingham Hematology & Oncology Associates Llc, Birmingham, Alabama, United States
🇺🇸Rocky Mountain Cancer Centers, Aurora, Colorado, United States
🇺🇸Texas Oncology Sammons Cancer Center, Dallas, Texas, United States
Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction
- Conditions
- Chronic Hepatitis B Virus InfectionChronic Hepatitis C Virus Infection
- Interventions
- Biological: BMS-914143 (Peginterferon Lambda-1a)
- First Posted Date
- 2012-10-17
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 43
- Registration Number
- NCT01708889
- Locations
- 🇺🇸
New Orleans Center For Clinical Research - Knoxville, Knoxville, Tennessee, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Clinical Pharmacology Of Miami Inc., Miami, Florida, United States
Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic Disorder
- First Posted Date
- 2012-10-16
- Last Posted Date
- 2021-03-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 49
- Registration Number
- NCT01707394
- Locations
- 🇺🇸
Connecticut Children's Medical Center, Hartford, Connecticut, United States
🇺🇸Childrens Hospital Of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Children's Hopsital Of Pittsburgh Of UPMC, Pittsburgh, Pennsylvania, United States
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
- Conditions
- Malignant Melanoma
- Interventions
- Biological: Ipilimumab
- First Posted Date
- 2012-09-28
- Last Posted Date
- 2017-08-29
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 14
- Registration Number
- NCT01696045
- Locations
- 🇺🇸
Phoenix Children'S Hospital, Phoenix, Arizona, United States
🇺🇸Childrens Hospital Of La, Los Angeles, California, United States
🇺🇸Children'S Hospital Colorado, Aurora, Colorado, United States
Description of Joint Population and Assessment of Impact on Health Status of Orencia in Patients With Rheumatoid Arthritis in France. A Database Analysis Based on SFR's ORA Long-term Cohort Study
- First Posted Date
- 2012-09-27
- Last Posted Date
- 2017-05-10
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT01694693